KOD stock surged +39% over the past 30 days, driven primarily by positive Phase 3 GLOW2 trial results for Zenkuda in diabetic retinopathy. Over the past quarter, shares gained +36%, reflecting anticipation of clinical catalysts and a successful $184 million capital raise.

WVE stock plunged approximately -52% over the past 30 days, driven primarily by disappointing high-dose data from the Phase 1 INLIGHT trial of obesity candidate WVE-007 on March 26, which erased prior gains from positive initial results. Over the past quarter, shares declined around -61%, reflecting high volatility in biotech sentiment amid clinical trial outcomes and broader sector pressures on clinical-stage firms

I've been following Rocket Pharmaceuticals (RCKT) closely as a late-stage biotech focused on gene therapies for rare pediatric diseases, using both lentiviral vector (LVV) and adeno-associated virus (AAV) platforms. What stands out to me is the company's strategic shift toward AAV-based cardiovascular programs—Danon disease, PKP2-ACM, and BAG3-DCM—which target areas with significant unmet needs and larger markets compared to traditional hematology indications. The recent FDA approval of KRESLADI marks Rocket's entry into commercialization, giving the team valuable launch experience and confirming the strength of its manufacturing setup.

I've been following Viridian Therapeutics (VRDN) closely, and the stock has seen quite a bit of turbulence lately due to key updates in its thyroid eye disease (TED) portfolio. Shares dropped sharply after the Phase 3 topline data for the subcutaneous candidate elegrobart came out, even though it hit the primary endpoint. Investors reacted to efficacy and safety results that didn't quite match the high expectations. Trading volume spiked dramatically, which shows just how much attention the market is paying. From what I see, sentiment is still linked to the company's pipeline progress, including the FDA review of the intravenous asset veligrotug. Near-term pressures are there, but with solid cash reserves and several catalysts ahead, VRDN remains a compelling biotech play for those who can handle the volatility.

I've been following Viridian Therapeutics ($VRDN) closely as it carves out a strong position in the thyroid eye disease (TED) market—a rare autoimmune disorder that causes orbital inflammation, proptosis, diplopia, and even vision loss in severe cases. The company draws on its antibody discovery and protein engineering expertise to create differentiated IGF-1R inhibitors, building on the validated pathway pioneered by Tepezza (teprotumumab). What stands out to me is how veligrotug diverges from Tepezza's frequent IV infusions: it offers a more convenient 12-week course with robust efficacy demonstrated in Phase 3 trials for both active and chronic TED, which could help it gain market share through better patient tolerability.

CNTA shares surged approximately +45.32% in Tuesday's session, climbing from a prior close of $27.58 to approximately $40.08, driven entirely by a blockbuster acquisition announcement. Primary catalyst: Eli Lilly and Company (LLY) announced a definitive agreement to acquire Centessa Pharmaceuticals for $38.00 per share in cash, plus one contingent value right (CVR) worth up to $9.00 per share, for total potential consideration of up to $47.00 per share.

PEPG shares are down approximately 64% in intraday trading on March 31, 2026, from a prior close of $4.23 to roughly $1.52, building on steep after-hours losses recorded on March 30. The primary catalyst is deeply disappointing Phase 2 clinical trial data from the FREEDOM2-DM1 study of PGN-EDODM1, PepGen's lead asset for myotonic dystrophy type 1 (DM1) — the drug showed virtually no benefit over placebo at the tested dose.

APLS shares surged approximately +138.56% in premarket trading on March 31, 2026, from a prior close of $17.09 to a premarket price of approximately $40.77. The primary catalyst is a definitive acquisition agreement announced by Biogen (BIIB), which agreed to acquire all outstanding shares of Apellis for $41.00 per share in cash, representing an upfront equity consideration of approximately $5.6 billion.

Northwest Biotherapeutics, Inc. (NWBO) is a clinical-stage biotechnology company focused on developing personalized immune therapies, primarily dendritic cell-based vaccines under its DCVax platform. The company's lead candidate, DCVax-L, targets glioblastoma multiforme (GBM), a lethal brain cancer, following completion of a Phase III trial. DCVax-Direct addresses inoperable solid tumors, with Phase I/II data available. NWBO operates in the competitive immunotherapy sector against players like large-cap biotechs, relying on a proprietary manufacturing process for cost-effective production.

Shares of Viridian Therapeutics (VRDN) are down approximately 32% in premarket trading on March 30, 2026, against a prior closing price of $27.39 on March 27, 2026, implying a premarket price near $18.63. The primary catalyst is the release of topline Phase 3 REVEAL-1 clinical trial data for elegrobart (VRDN-003) in patients with active thyroid eye disease (TED), long anticipated as the company's most critical near-term de-risking event.

CRBU stock declined approximately -10% over the past 30 days, reflecting volatility amid clinical updates and financing concerns. Over the past quarter, the stock rose about +12%, driven by positive earnings beats and pipeline progress. Key drivers include Q4 2025 earnings beat, vispa-cel Phase 3 plans, but offset by cash burn and need for additional capital.

PGEN shares are surging approximately +30% in Thursday's trading session, from a prior close of $3.10 to approximately $4.03, as of mid-session on March 26, 2026. The primary catalyst is Precigen's blockbuster Q1 2026 revenue guidance — the company expects Q1 revenue to exceed $18 million, a staggering 429% sequential increase from Q4 2025's $3.4 million.

KOD shares surged approximately +50% in premarket trading on Thursday, March 26, 2026, from a prior closing price of $22.75 to approximately $34.13. The primary catalyst is a landmark readout: the GLOW2 Phase 3 trial of Zenkuda (tarcocimab tedromer) in diabetic retinopathy met its primary endpoint with overwhelming statistical significance.

Wave Life Sciences (WVE) shares are tumbling approximately 51% in premarket trading on March 26, 2026, from a prior close of $12.30 to approximately $6.03. The primary catalyst is the release of highly anticipated INLIGHT Phase 1 clinical data for WVE-007, the company's investigational INHBE GalNAc-siRNA obesity treatment, with results falling materially short of investor expectations.

Shares of ADMA are declining approximately 12% in Wednesday's session, extending a steep two-day selloff. The primary catalyst is a short-seller research report published by Culper Research on March 24, 2026, alleging that ADMA engaged in channel stuffing to artificially inflate revenue growth.

AVXL shares are down approximately 29% in premarket trading on Wednesday, March 25, 2026, falling to roughly $2.97 from the prior close of $4.19. The primary catalyst is Anavex's formal withdrawal of its marketing authorization application (MAA) for blarcamesine from the European Union, announced in the early hours of March 25, 2026.

Shares of Enliven Therapeutics (ELVN) are surging approximately +15% in premarket trading on March 25, 2026, driven by renewed investor enthusiasm around the company's advancing clinical program for ELVN-001 in chronic myeloid leukemia (CML). The stock's prior closing price on March 24, 2026 was $31.15, placing the premarket indicated price near $35.82.

MAZE shares are trading approximately 27% lower in premarket on March 25, 2026, after the company reported its highly anticipated Phase 2 HORIZON trial topline data for lead drug candidate MZE829. The catalyst is a dual announcement: Phase 2 clinical data for MZE829 in APOL1-mediated kidney disease (AMKD) alongside Q4 and full-year 2025 financial results.

IBRX shares are down approximately 23% in Tuesday's session, trading near $7.24 after closing at $9.40 on Monday, March 23. The sharp decline follows an 11%+ surge in the prior session, with profit-taking and valuation pressure cited as primary triggers.

Shares of Karyopharm Therapeutics (KPTI) are trading approximately 12% lower in Tuesday's premarket session, with the previous close at $7.63. The primary catalyst is the March 24 release of topline Phase 3 SENTRY trial data, in which the company met only one of two co-primary endpoints.